These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Prescription for trouble: common drugs, hidden dangers. Tens of people are at risk. Consum Rep; 2006 Jan; 71(1):34-9. PubMed ID: 16491527 [No Abstract] [Full Text] [Related]
3. Reporting adverse effects: a practice to be encouraged. Prescrire Int; 2013 Mar; 22(136):83. PubMed ID: 23593701 [No Abstract] [Full Text] [Related]
4. Communicating the risks of medicines: time to move forward. Dal Pan GJ Med Care; 2012 Jun; 50(6):463-5. PubMed ID: 22581011 [No Abstract] [Full Text] [Related]
5. [What medicine in gynecology and obstetrics for the future?]. Fernandez H; J Gynecol Obstet Biol Reprod (Paris); 2013 Jun; 42(4):305-6. PubMed ID: 23608348 [No Abstract] [Full Text] [Related]
6. Curbing industry sponsor's incentive to design post-approval trials that are suboptimal for informing prescribers but more likely than optimal designs to yield favorable results. Falit BP Seton Hall Law Rev; 2007; 37(4):969-1049. PubMed ID: 18363220 [No Abstract] [Full Text] [Related]
8. Unlicensed and off-label drug use in children. Bavdekar SB; Gogtay NJ J Postgrad Med; 2005; 51(4):249-52. PubMed ID: 16388164 [No Abstract] [Full Text] [Related]
9. Striking the right balance. Nat Rev Drug Discov; 2006 Nov; 5(11):879. PubMed ID: 17117516 [No Abstract] [Full Text] [Related]
10. Historical development of pediatric pharmacology. Seyberth HW; Rane A; Schwab M Handb Exp Pharmacol; 2011; 205():v-vi. PubMed ID: 22046631 [No Abstract] [Full Text] [Related]
11. FDA attempting to overcome major roadblocks in monitoring drug safety. Zielinski SL J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645 [No Abstract] [Full Text] [Related]
13. Drug safety and regulation. Waller PC; Evans SJ; Beard K BMJ; 2005 Jul; 331(7507):4-5. PubMed ID: 15994664 [No Abstract] [Full Text] [Related]
14. Post-approval drug research: objectives and methods. Schäfer H Pharmacopsychiatry; 1997 Jan; 30(1 Suppl):4-8. PubMed ID: 9035222 [TBL] [Abstract][Full Text] [Related]
15. Current status of the drug safety monitoring system in Korea. Park BJ Pharmacoepidemiol Drug Saf; 2001; 10(6):557-60. PubMed ID: 11828840 [No Abstract] [Full Text] [Related]
16. Short patent lives jeopardize drug and patient safety. Hondeghem LM; De Clerck F; Camm J J Cardiovasc Pharmacol; 2007 Oct; 50(4):353-7. PubMed ID: 18049301 [TBL] [Abstract][Full Text] [Related]
17. Safety in numbers--monitoring risk in approved drugs. Okie S N Engl J Med; 2005 Mar; 352(12):1173-6. PubMed ID: 15788493 [No Abstract] [Full Text] [Related]
18. Should new drugs be avoided? Child Health Alert; 2002 Jun; 20():2. PubMed ID: 12096722 [No Abstract] [Full Text] [Related]
19. Deterring inefficient pharmaceutical litigation: an economic rationale for the FDA regulatory compliance defense. Viscusi WK; Rowland SR; Dorfman HL; Walsh CJ Spec Law Dig Health Care Law; 1996 Mar; (205):9-52. PubMed ID: 10156421 [No Abstract] [Full Text] [Related]
20. [Regulatory guidelines and drug safety]. Flury W Ther Umsch; 1993 Jan; 50(1):49-51. PubMed ID: 8378867 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]